Equillium Rockets 99% on $50M Financing to Advance Novel Autoimmune Therapy
Equillium, Inc. (EQ) soared 99.21% to lead the PRISM Emerging Biotech Index after announcing a definitive securities purchase agreement for up to $50 million in gross proceeds. The deal, led by ADAR1 Capital Management and Janus Henderson Investors, includes $30 million upfront with the potential for an additional $20 million tied to clinical milestones. Proceeds will advance EQ504, a potent aryl hydrocarbon receptor modulator, into a Phase 1 proof-of-mechanism study for ulcerative colitis and pouchitis by mid-2026, with data expected within six months. Management highlighted EQ504’s non-immunosuppressive, multi-modal mechanism as a potentially differentiated approach in inflammation and immunology.
Telos Jumps 52% on Strong Q2 Results and Cybersecurity Demand
Telos Corporation (TLS) climbed 52.31%, boosting the PRISM Emerging Cybersecurity Index, following the release of its Q2 2025 results. While full financial details were not disclosed in the headline, the company highlighted ongoing momentum across its cyber, cloud, and enterprise security solutions, serving some of the most security-conscious organizations worldwide. Investors responded positively to continued demand in regulated industries and government sectors, as well as Telos’ positioning in identity and access management, secure mobility, and IT risk management.
Other PRISM Mid-Day Movers:
• Bitmine Immersion Technologies Inc. (BMNR) up 34.00%
• Village Farms International Inc. (VFF) up 29.32%
• WM Technology Inc. (MAPS) up 29.25%
• IO Biotech Inc (IOBT) down 24.03%
The post PRISM Mid-Day Movers: Biotech Financing Frenzy and Cybersecurity Surge appeared first on PRISM MarketView.
